Exploring new chemical compounds for potential anti-cancer and anti-malarial treatments
Official title: Harnessing divergent reactivities of unusual reactive intermediates as platforms to explore high Fsp3 amine chemical space
Funded at University of Wisconsin-Madison · NIH-11146397 · Data updated 2026-11-12
This study is exploring new ways to make important molecules that could help treat cancer and malaria, using simple building blocks to create more complex structures that are often found in medicines.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Wisconsin-Madison NIH-funded |
| Lab location | 1 site (Madison, United States) |
| Project start | August 1, 2024 |
| Project end | May 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $448,279 |
| NIH project number | 5R35GM152043-02 |
| Project ID | NIH-11146397 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research would be individuals with cancer or malaria who are seeking new treatment options.
✕Less likely to help
Patients who are not affected by cancer or malaria may not receive any benefit from this research.
What this research studies
This research focuses on developing innovative synthetic methods to create complex molecules that could be important for human health, particularly in the fields of cancer and malaria treatment. The team is working on two platforms that transform simple chemical precursors into more complex structures, specifically targeting N-heterocycles and amine-bearing carbocycles, which are common in many drugs. By utilizing mechanistic insights, they aim to manipulate reactive intermediates to produce a variety of stereochemically rich compounds that could lead to new therapeutic agents.
Why it matters
Potential benefit: If successful, this research could lead to the discovery of new drugs that are more effective in treating cancer and malaria.
How similar studies have gone: Other research has shown promise in developing new synthetic methods for drug discovery, indicating that this approach could yield significant results.
Where this research is happening
-
University of Wisconsin-Madison
Madison, United States Active
Researchers
- Principal investigator: Schomaker, Jennifer Marie — University of Wisconsin-Madison
- Study coordinator: Schomaker, Jennifer Marie
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.